Is ProQR Therapeutics NV overvalued or undervalued?

As of 4 November 2021, ProQR Therapeutics NV has moved from a grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.44, an EV to EBIT of -1.92, and an EV to Sales of 3.42, which indicate significant financial distress and lack of profitability.
In comparison to its peers, ProQR's P/E ratio stands at -6.2227, while Talaris Therapeutics, Inc. has a P/E of -5.6255, and Eton Pharmaceuticals, Inc. shows a staggering P/E of -92.8956. These figures highlight the challenges faced by ProQR in maintaining a competitive valuation within its industry. Despite a recent positive stock return of 16.77% over the past month, the overall performance year-to-date remains negative at -26.42%, reinforcing the notion that the company is overvalued in its current state.